Prax­is rais­es $110 mil­lion to tar­get CNS dis­ease with Phase II drugs

Just two months af­ter burst­ing on­to the neu­ro­science scene, Prax­is Pre­ci­sion Med­i­cines has added $110 mil­lion in fund­ing to pur­sue ther­a­pies for cen­tral ner­vous sys­tem dis­or­ders.

Prax­is came out of stealth mode in May af­ter bank­ing $100 mil­lion in fund­ing and putting two drugs in Phase II de­vel­op­ment. While Big Phar­ma has strayed away from neu­ro­science, Prax­is set out to iden­ti­fy mu­ta­tions that cause epilep­sy in pa­tients who did not in­her­it the dis­ease. The com­pa­ny is now ap­ply­ing its dis­cov­er­ies to po­ten­tial treat­ments for oth­er CNS dis­eases, such as de­pres­sion, epilep­sy, move­ment dis­or­ders and pain syn­dromes. It has three drugs in the clin­i­cal pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER